Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Thymosin Alpha-1 + Thymalin Protocol
TA1/Thymalin Stack, Immune Peptide Protocol
A combination protocol pairing Thymosin Alpha-1 (a 28-amino acid thymic peptide) with Thymalin (a thymic extract) for comprehensive immune system modulation. Based on the work of Vladimir Khavinson, this stack targets both innate and adaptive immunity. Used in integrative medicine for immune optimization, post-illness recovery, and longevity protocols.
A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.
Thymosin Alpha-1 activates dendritic cells, enhances T-cell maturation, and modulates Th1/Th2 balance. Thymalin provides a broader spectrum of thymic peptides that support thymic function and T-cell diversity. Together, they address both the specific (TA1) and general (Thymalin) aspects of thymic immune regulation.
Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.
- Comprehensive immune optimization
- Post-viral recovery protocols
- Chronic infection support
- Longevity and immune aging (immunosenescence)
- Pre-travel immune preparation
- Immune system support
- Chronic infection management
- Cancer adjunct therapy (in some countries)
- Post-illness recovery
- Autoimmune condition management
- Injection site reactions from both peptides
- Potential for immune overstimulation
- Autoimmune flare risk in predisposed individuals
- Cost — both peptides required
- Limited data on combination safety
- Generally well-tolerated in clinical use
- Injection site reactions
- Rare allergic reactions
- May interact with immunosuppressive drugs
Thymosin Alpha-1 is FDA-approved internationally (Zadaxin) but not in the US. Thymalin has no FDA status. The combination protocol is not FDA-reviewed. Both are available through compounding pharmacies. TA1 is on the 503A Category 1 bulks list.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.